Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL575118 | 1.00 | CYP3A4 (0.85) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL381001 | 1.00 | CYP3A4 (0.85) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3821071 | 0.95 | CYP3A4 (0.77) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL575195 | 0.95 | CYP3A4 (0.77) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3818429 | 0.93 | CYP3A4 (0.74) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3816073 | 0.93 | CYP3A4 (0.74) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3813564 | 0.93 | CYP3A4 (0.74) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL1295773 | 0.93 | CYP3A4 (0.73) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL3816946 | 0.93 | CYP3A4 (0.73) | CYP3A4TSHRLPAR3LPAR1LPAR2 | |
| SCHEMBL1020179 | 0.92 | CYP3A4 (1.00) | CYP3A4TSHRLPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194778-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LTD (GB) | 2017-01-18 | — | — | EP | disclosed |
| EP-2194779-B1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-20110230437-A1 | ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| EP-2194778-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Syngenta Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| EP-2194779-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Syngenta Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027624-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009027626-A2 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230437-A1 | ORGANIC COMPOUNDS | NR2C2, NR1H3, HRH4 | CYP3A4 194/4885TSHR 659/4885LPAR3 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.